Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Let’s get it.
I placed it as a sticky for now.
Anavex science is all that matters and not one persons opinion.
Bring on the results.
My profit is decreasing. Keep pumping.
It sure appears it’s trying to get to $20. I added on the dip.
Nice move again. Keep it coming.
must
verb
1.
be obliged to; should (expressing necessity).
"you must show your ID card"
Similar:
ought to
should
have to
have got to
need to
be obliged to
be required to
be compelled to
be under an obligation to
2.
expressing an opinion about something that is logically very likely.
"there must be something wrong
Must defined. Anavex must do better.
Covid results being peered reviewed and manuscript is posted.
Superb early positive results from a very conservative company. Major trials starting end of this month.
We are around 9 months post top line, when do you think full data set is coming?
Looks like another buying opportunity is coming. Last add was $202.
Nice price movement. I got in @ $11. This looks super strong. Superb year for profits.
Nice to see the SP continue to reflect the progress. A big shout out to Dr Patterson. Tedx was the catalyst.
Have a good trading day.
Still does not preclude or exclude Missling from being an ass.
I hope to make more money from the ass.
Just because I invest in a company does not mean I have to like the company or directors.
Profit is profit.
The Tedx talk is discussing the efficacy of a particular drug. Not $.
375 shares purchase of a $3 stock from a CEO was purely childish. Character matters but has nothing to do with the science.
We are holding shares to see the hand. Best wishes.
Missling is an ass.
Wow.. Oh oooookkkkkkaaaayyyyy.
The good ole 375 Missling share purchase program. Juvenile.
Most Covid plays follow this same pattern. Profit taking.
Lol $6.30 to $2.40. Told you a week ago to dump it. Why buy at $6 $5, $4 or $3 when you can buy at $2.40. Lol, some said it was going to $10 last week and we said pump and dump. But but JPM yada yada. But but we follow the big money. Big money got a sweet deal and retail gets the pipe.
Don’t believe the hype on 12 cherrypicked patients.
Buy low. Lol.
$6.30 down to $3’s. Yeah we call that a pump based upon headlines. RSI was too high for my liking. We said make your money and get out. If it holds $3.30 to $3.40 it might be good to get in. If it doesn’t hold, ????
SP has nothing to do with efficacy of clinical. Best wishes.
Goodwill moving us up in premarket? I added last week and nice to see a green start to the week.
AstraZeneca to supply Europe with up to 400 million
doses of Oxford University's vaccine at no profit
Company exploring further additional global
capacity to provide broad and equitable access
AstraZeneca has reached an agreement with Europe's Inclusive Vaccines Alliance (IVA), spearheaded by Germany, France, Italy and the Netherlands, to supply up to 400 million doses of the University of Oxford's COVID-19 vaccine, with deliveries starting by the end of 2020.
Wrong. Humanigen. Cherrypicked pick the patients and data.
The ARDS exclusion and no companion trial testing patients with ARDS says all we need to know.
All the other trials this company had going prior to Covid is superb. Sarcasm.
This is a TRADE.
Lilly is not a Martin shkreli sequel either.
Lilly's COVID-19 drug, specifically designed to treat the virus, could be authorized for use by September.
Authorized for use by September per the headline. That’s an impressive headline. Great company.
Kind of like 2-73. No efficacy for anyone with A score below 20.
No PET on original 32 and etc.
I cut my criteria teeth there years ago. Lenzi excludes ARDS is a Gilead move. Money can be made but another company is working on ARDS and this will be short lived.
hydroxychloroquine is being tested all over the world and we know what that’s worth.
Superb news on the expansion.
I’m going to continue to add.
Trial inclusion and exclusion matter. Lenzil excludes folks with confirmed Acute Respiratory Distress syndrome and Leronlimab wants those patients and the most terminally ill in their trial.
Two different leagues. Sorry.
A poster can be Elvis it appears. Also trial inclusions and exclusions matter. If not similar you are comparing apples to oranges.
Anavex delayed opening new sites to drag their feet and dilute more knowing that don’t have a viable AD drug.
The question is why did the company wait almost two years to open more locations. It appears the AD trial delays were planned.
I agree. I’m going to add based upon all of the new Price Targets.
Repost from Trenddetector
Repost of my "List of catalysts that can happen any day now:"
1) FDA emergency approval of leronlimab for COVID-19
2) Government grant to pay for production of leronlimab
3) Phase 2b/3 results for COVID-19
4) Phase 1/2 results for COVID-19
5) Major media exposure - its bound to happen soon
6) High profile testimonial/new COVID-19 patient
7) Many more to follow once any one of the above happen
He’s been quiet lately so it will be refreshing to hear him chat. Thanks for the notice.
Missling has been gifted enough shares. Shares for reaching 50% AD enrollment for example.
I agree, long term it should continue to move in a normal market. With the selling the news and market uncertainty, I didn’t roll my 7’s that expired yesterday. I already sold the 6’s. I took the cash and will look to return next week. The return was exceptional.
Super interview today. Thanks for posting.